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The metabolic syndrome has received increased attentionin the past few years. This statement from the American
Heart Association (AHA) and the National Heart, Lung, and
Blood Institute (NHLBI) is intended to provide up-to-date
guidance for professionals on the diagnosis and management
of the metabolic syndrome in adults.
The metabolic syndrome is a constellation of interrelated
risk factors of metabolic origin—metabolic risk factors—that
appear to directly promote the development of atherosclerotic
cardiovascular disease (ASCVD).1 Patients with the metabol-
ic syndrome also are at increased risk for developing type 2
diabetes mellitus. Another set of conditions, the underlying
risk factors, give rise to the metabolic risk factors. In the past
few years, several expert groups have attempted to set forth
simple diagnostic criteria to be used in clinical practice to
identify patients who manifest the multiple components of the
metabolic syndrome. These criteria have varied somewhat in
specific elements, but in general they include a combination
of both underlying and metabolic risk factors.
The most widely recognized of the metabolic risk factors
are atherogenic dyslipidemia, elevated blood pressure, and
elevated plasma glucose. Individuals with these characteris-
tics commonly manifest a prothrombotic state and a pro-
inflammatory state as well. Atherogenic dyslipidemia con-
sists of an aggregation of lipoprotein abnormalities including
elevated serum triglyceride and apolipoprotein B (apoB),
increased small LDL particles, and a reduced level of HDL
cholesterol (HDL-C). The metabolic syndrome is often re-
ferred to as if it were a discrete entity with a single cause.
Available data suggest that it truly is a syndrome, ie, a
grouping of ASCVD risk factors, but one that probably has
more than one cause. Regardless of cause, the syndrome
identifies individuals at an elevated risk for ASCVD. The
magnitude of the increased risk can vary according to which
components of the syndrome are present plus the other,
non–metabolic syndrome risk factors in a particular person.
Underlying Risk Factors and
Metabolic Syndrome
The predominant underlying risk factors for the syndrome
appear to be abdominal obesity2–4 and insulin resistance5,6;
other associated conditions can be physical inactivity,3,7
aging,8 and hormonal imbalance.9 An atherogenic diet (eg, a
diet rich in saturated fat and cholesterol) can enhance risk for
developing cardiovascular disease in people with the syn-
drome, although this diet is not listed specifically as an
underlying risk factor for the condition.1 One theory holds
that insulin resistance is the essential cause of the metabolic
syndrome.10 There is no doubt that insulin resistance predis-
poses to the hyperglycemia of type 2 diabetes mellitus.
Multiple metabolic pathways have also been proposed to link
insulin resistance and compensatory hyperinsulinemia to the
other metabolic risk factors.10,11 It is recognized that some
people who are not obese by traditional measures neverthe-
less are insulin resistant and have abnormal levels of meta-
bolic risk factors. Examples are seen in individuals with 2
diabetic parents or 1 parent and a first- or second-degree
relative12; the same is true for many individuals of South
Asian ethnicity.13,14 Although insulin-resistant individuals
need not be clinically obese, they nevertheless commonly
have an abnormal fat distribution that is characterized by
predominant upper body fat. Upper-body obesity correlates
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strongly with insulin resistance. Excess upper body fat can
accumulate either intraperitoneally (visceral fat) or subcuta-
neously. Many investigators claim that excess visceral fat is
more strongly associated with insulin resistance than any
other adipose tissue compartment4,15–21; other workers find
that excess subcutaneous abdominal (or truncal) fat also
carries a significant association with insulin resistance.22–27
Regardless of the relative contributions of visceral fat and
abdominal subcutaneous fat to insulin resistance, a pattern of
abdominal (or upper-body) obesity correlates more strongly
with insulin resistance and the metabolic syndrome than does
lower-body obesity.28 An interesting feature of upper-body
obesity is an unusually high release of nonesterified fatty
acids from adipose tissue12,14,28; this contributes to accumu-
lation of lipid in sites other than adipose tissue. Ectopic lipid
accumulation in muscle and liver seemingly predisposes to
insulin resistance29 and dyslipidemia.30
According to many experts, the increasing burden of
obesity in the United States is the driving force behind the
rising prevalence of the metabolic syndrome.1–4,31,32 This
view needs to be harmonized with the insulin resistance
hypothesis. Abnormalities in adipose tissue metabolism may
be the crux of the issue. Adipose tissue in obese people is
insulin resistant, which raises nonesterified fatty acid levels,
worsening insulin resistance in muscle29,33 and altering he-
patic metabolism31; in addition, the adipose tissue of obesity
exhibits abnormalities in the production of several adipokines
that may separately affect insulin resistance and/or modify
risk for ASCVD.34 These include increased production of
inflammatory cytokines,35,36 plasminogen activator inhibitor-
1,37 and other bioactive products38–40; at the same time the
potentially protective adipokine, adiponectin, is reduced.41,42
All of these changes have been implicated as causes of the
metabolic risk factors. Indeed, as mentioned before, some
individuals exhibit the metabolic syndrome with only a
moderate degree of total body obesity.43,44 Notable are many
South Asians who appear to be inherently insulin resistant,45
a condition that is exacerbated by mild abdominal obesity.14
Moreover, the population of the United States varies consid-
erably in degree of insulin resistance46; those having more
inherent insulin resistance can develop the metabolic syn-
drome with only moderate excess in abdominal fat,43,44 but
even people with little or no inherent insulin resistance can
develop the metabolic syndrome if they accumulate marked
abdominal obesity.3,8 These findings support the idea that
body fat distribution, particularly excess abdominal fat, plays
an important role in the etiology of the syndrome.
Recently, this syndrome has been noted to be associated
with a state of chronic, low-grade inflammation.47,48 Some
researchers speculate that inflammation of this type underlies
or exacerbates the syndrome. For example, inflammatory
cytokines reportedly induce insulin resistance in both adipose
tissue and muscle.48–51 In the presence of obesity, adipose
tissue indeed produces cytokines in excess, whereas output of
adiponectin is diminished; these responses appear to heighten
the connection between obesity and inflammation.35 Interest-
ingly, insulin-resistant people manifest evidence of low-grade
inflammation even without an increase of total body fat.52
Finally, considerable individual and ethnic variation exists
in the clinical pattern of metabolic risk factors in obese/
insulin-resistant subjects.53,54 It is likely that the expression of
each metabolic risk factor falls partially under its own genetic
control, which influences the response to different environ-
mental exposures. For example, a variety of polymorphisms
in genes affecting lipoprotein metabolism are associated with
worsening of dyslipidemia in obese people.55,56 Similarly, a
genetic predisposition to defective insulin secretion when
combined with insulin resistance can raise plasma glucose to
abnormal levels.57
Although the metabolic syndrome unequivocally predis-
poses to type 2 diabetes mellitus,48,58–62 many investigators of
cardiovascular diseases consider this syndrome to be a
multidimensional risk factor for ASCVD.1,58 Several recent
reports show that the metabolic syndrome is associated with
greater risk for cardiovascular disease,63–73 but once type 2
diabetes mellitus emerges, cardiovascular risk increases even
more.74 Finally, insulin resistance and the metabolic syn-
drome are associated with a variety of other conditions75–77;
some of these are fatty liver,30,78 polycystic ovary syn-
drome,79 cholesterol gallstones,80 sleep apnea,81 lipodystro-
phies,82 and protease-inhibitor therapy for HIV.83 These
associations are generating considerable interest in several
other fields of medicine.
Metabolic Risk Factors, ASCVD, and Type 2
Diabetes Mellitus
The metabolic risk factors consist of those factors that
seemingly have a direct effect on atherosclerotic disease.
Among these, as stated earlier, atherogenic dyslipidemia
consists of an aggregation of lipoprotein abnormalities in-
cluding elevated serum triglyceride and apoB, increased
small LDL particles, and a reduced level of HDL-C.1 Among
triglyceride-rich lipoproteins, remnant lipoproteins almost
certainly are the most atherogenic.1 Many studies further
suggest that the smallest particles in the LDL fraction carry
the greatest atherogenicity.84 The atherogenic potential of
lipoprotein remnants and small LDL could be confounded in
part by their common association with an increased total
number of apoB-containing lipoproteins in circulation; this
increased number is reflected by an elevation of serum total
apoB.85–89 Finally, the lipoprotein field widely holds that low
levels of HDL are independently atherogenic1; multiple
mechanisms are implicated to explain this relationship.90
Other metabolic risk factors likewise appear individually to
be atherogenic. Among these are hypertension, elevated
plasma glucose, a prothrombotic state, and a proinflamma-
tory state. Indeed, 3 of the metabolic risk factors—elevated
apoB-containing lipoproteins,1 low HDL-C levels,1 and hy-
pertension91—are well established, major risk factors. Each
imparts increased risk even when only marginally abnormal,
as often observed in the metabolic syndrome. A growing
body of data additionally implicates high circulating levels of
prothrombotic factors in the causation of ASCVD events,
possibly by predisposing to thrombotic episodes.92–94 Many
reports also show that the presence of a proinflammatory
state, as revealed by increased inflammatory markers,95,96
denotes a higher risk for acute cardiovascular syndromes.
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Finally, a variety of mechanisms to explain how elevated
plasma glucose may promote atherosclerosis are postulated.97
Regardless, once type 2 diabetes mellitus compounds the
metabolic syndrome, risk for ASCVD events increases still
more.
Clinical Diagnosis of Metabolic Syndrome
Many investigations confirm that multiple cardiovascular risk
factors of endogenous origin commonly aggregate in one
individual. Although this aggregation was originally observed
many years ago,98,99 more recently, several terms have been
proposed to describe this clustering: metabolic syndrome,100
syndrome X,101 the “deadly quartet,”102 insulin-resistance
syndrome,103,104 and hypertriglyceridemic waist.105 The term
metabolic syndrome is most commonly used in the cardio-
vascular field. Although the metabolic syndrome is often
referred to as a discrete entity, it is important to recognize, as
noted earlier, that it is a syndrome and not a defined uniform
entity. No single pathogenesis has been elucidated, nor may
one exist. Thus, the syndrome could range from a cluster of
unrelated risk factors to a constellation of risk factors linked
through a common underlying mechanism. From a clinical
standpoint, presence of the metabolic syndrome identifies a
person at increased risk for ASCVD and/or type 2 diabetes
mellitus. Eventually, a better understanding of the specific
cause(s) of the syndrome may provide an improved estimate
of risk of developing ASCVD or type 2 diabetes mellitus for
individuals. For now, however, the presence of the syndrome
is a more general indicator of higher risk for these conditions.
Because of a documented high relative risk for ASCVD
events and type 2 diabetes mellitus, the metabolic syndrome
undoubtedly carries a relatively high lifetime risk for these
disorders even when shorter-term (10-year) risk is in the
low-to-moderate range.63–73
In the effort to introduce the metabolic syndrome into
clinical practice, several organizations have attempted to
formulate simple criteria for its diagnosis (Table 1). The first
proposal came in 1998 from a consultation group on the
definition of diabetes for the World Health Organization
(WHO).106 This group emphasized insulin resistance as the
major underlying risk factor and required evidence of insulin
resistance for diagnosis. This followed on the widely held
belief that insulin resistance is the primary cause of the
syndrome. A diagnosis of the syndrome by WHO criteria
could thus be made when a patient exhibited one of several
markers of insulin resistance plus 2 additional risk factors.
Although insulin resistance is difficult to measure directly in
a clinical setting, several types of indirect evidence were
accepted, ie, impaired glucose intolerance [IGT], impaired
fasting glucose [IFG], type 2 diabetes mellitus, or impaired
disposal of glucose under hyperinsulinemic, euglycemic con-
ditions. The other risk factors used for diagnosis included
obesity, hypertension, high triglycerides, reduced HDL-C
level, or microalbuminuria. The consultation group suggested
categorical cutpoints to define each of these factors. Impor-
tantly, the WHO group allowed the term metabolic syndrome
to be used in patients with type 2 diabetes mellitus who
otherwise met the requirements for the syndrome. They
reasoned that patients with type 2 diabetes mellitus often have
a clustering of ASCVD risk factors, which puts them at
particularly high risk for ASCVD.69,70
In 1999, the European Group for Study of Insulin Resis-
tance (EGIR) proposed a modification of the WHO defini-
tion.107 This group used the term insulin resistance syndrome
TABLE 1. Previous Criteria Proposed for Clinical Diagnosis of Metabolic Syndrome
Clinical Measure WHO (1998) EGIR ATP III (2001) AACE (2003) IDF (2005)
Insulin resistance IGT, IFG, T2DM, or lowered insulin
sensitivity*
plus any 2 of the following
Plasma insulin 75th percentile
plus any 2 of the following
None,
but any 3 of the following 5
features
IGT or IFG
plus any of the
following based on
clinical judgment
None
Body weight Men: waist-to-hip ratio 0.90;
women: waist-to-hip ratio 0.85
and/or BMI 30 kg/m2
WC 94 cm in men or
80 cm in women
WC 102 cm in men or
88 cm in women†
BMI 25 kg/m2 Increased WC (population
specific)
plus any 2 of the following
Lipid TG 150 mg/dL and/or HDL-C
35 mg/dL in men or 39 mg/dL
in women
TG 150 mg/dL and/or HDL-C
39 mg/dL in men or women
TG 150 mg/dL
HDL-C 40 mg/dL in men or
50 mg/dL in women
TG 150 mg/dL and
HDL-C 40 mg/dL in
men or 50 mg/dL in
women
TG 150 mg/dL or on TG Rx
HDL-C 40 mg/dL in men or
50 mg/dL in women or on
HDL-C Rx
Blood pressure 140/90 mm Hg 140/90 mm Hg or on
hypertension Rx
130/85 mm Hg 130/85 mm Hg 130 mm Hg systolic or
85 mm Hg diastolic or on
hypertension Rx
Glucose IGT, IFG, or T2DM IGT or IFG (but not diabetes) 110 mg/dL (includes
diabetes)‡
IGT or IFG (but not
diabetes)
100 mg/dL (includes
diabetes)
Other Microalbuminuria Other features of
insulin resistance§
T2DM indicates type 2 diabetes mellitus; WC, waist circumference; BMI, body mass index; and TG, triglycerides. All other abbreviations as in text.
*Insulin sensitivity measured under hyperinsulinemic euglycemic conditions, glucose uptake below lowest quartile for background population under investigation.
†Some male patients can develop multiple metabolic risk factors when the waist circumference is only marginally increased (eg, 94 to 102 cm 37 to 39 in). Such
patients may have a strong genetic contribution to insulin resistance. They should benefit from changes in lifestyle habits, similar to men with categorical increases
in waist circumference.
‡The 2001 definition identified fasting plasma glucose of 110 mg/dL (6.1 mmol/L) as elevated. This was modified in 2004 to be 100 mg/dL (5.6 mmol/L), in
accordance with the American Diabetes Association’s updated definition of IFG.46,47,77
§Includes family history of type 2 diabetes mellitus, polycystic ovary syndrome, sedentary lifestyle, advancing age, and ethnic groups susceptible to type 2 diabetes
mellitus.
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rather than metabolic syndrome. They likewise assumed that
insulin resistance is the major cause and required evidence of
it for diagnosis. By their criteria, plasma insulin levels in the
upper quartile of the population defined insulin resistance. An
elevated plasma insulin plus 2 other factors—abdominal
obesity, hypertension, elevated triglycerides or reduced
HDL-C, and elevated plasma glucose—constituted a diagno-
sis of the insulin-resistance syndrome. Notably, EGIR fo-
cused more on abdominal obesity than did WHO, but in
contrast to WHO, EGIR excluded patients with type 2
diabetes mellitus from their syndrome because insulin resis-
tance was viewed primarily as a risk factor for diabetes.
In 2001, the National Cholesterol Education Program
(NCEP) Adult Treatment Panel III (ATP III) introduced
alternative clinical criteria for defining the metabolic syn-
drome.1 In so doing, the purpose of ATP III was to identify
people at higher long-term risk for ASCVD who deserved
clinical lifestyle intervention to reduce risk. The ATP III
criteria did not require demonstration of insulin resistance per
se. It was noted that direct measures of insulin resistance are
laborious and not well standardized. Moreover, less-specific
measures, such as glucose tolerance tests, are not routinely
used in clinical practice. Although the ATP III panel recog-
nized the phenomenon of clustering of metabolic risk factors,
it did not draw conclusions on mechanistic pathogenesis. The
ATP III criteria thus required no single factor for diagnosis,
but instead made the presence of 3 of 5 factors the basis for
establishing the diagnosis; these were abdominal obesity
(also highly correlated with insulin resistance), elevated
triglycerides, reduced HDL-C, elevated blood pressure, and
elevated fasting glucose (IFG or type 2 diabetes mellitus).
Although ATP III did not make any single risk factor (eg,
abdominal obesity) a requirement for diagnosis, it nonethe-
less espoused the position that abdominal obesity is an
important underlying risk factor for the syndrome. Its cut-
points for abdominal obesity came from the definition in the
1998 National Institutes of Health obesity clinical guide-
lines108; they were a waist circumference of 102 cm (40
in) for men and88 cm (35 in) for women. These cutpoints
identify approximately the upper quartile of the US popula-
tion. Abdominal obesity at these cutpoints was not made a
prerequisite for diagnosis because lesser degrees of abdomi-
nal girth often associate with other ATP III criteria. In fact,
some individuals or ethnic groups (eg, Asians, especially
South Asians) appear to be susceptible to development of the
metabolic syndrome at waist circumferences below ATP III
cutpoints. Thus, ATP III specifically noted that some indi-
viduals having only 2 other metabolic syndrome criteria
appear to be insulin resistant even when the waist circumfer-
ence is only marginally elevated, eg, 94 to 101 cm in men or
80 to 87 cm in women. If so, they should benefit from clinical
intervention similarly to many others who have greater
increases in waist circumference, ie, 102 cm (40 in) for
men and 88 cm (35 in) for women. ATP III, like WHO,
allowed for a diagnosis of metabolic syndrome in the pres-
ence of type 2 diabetes because of the high risk for ASCVD
among multiple-risk factor patients with diabetes. When type
2 diabetes mellitus is present, concomitant metabolic risk
factors must not be overlooked because of strong evidence
that intervention on them can substantially reduce risk for
ASCVD.
In 2003, the American Association of Clinical Endocrinol-
ogists (AACE) modified ATP III criteria to refocus on insulin
resistance as the primary cause of metabolic risk factors.109
Like the EGIR,107 they used the name insulin resistance
syndrome. Major criteria were IGT, elevated triglycerides,
reduced HDL-C, elevated blood pressure, and obesity. No
specified number of factors qualified for diagnosis, which
was left to clinical judgment. Other factors used to inform
clinical judgment were a family history of ASCVD or type 2
diabetes mellitus, polycystic ovary syndrome, and hyperuri-
cemia. By the AACE’s definition, once a person develops
type 2 diabetes mellitus, the term insulin resistance syndrome
no longer applies.
In 2005, the International Diabetes Foundation (IDF)
published new criteria that again modified the ATP III
definition.110 The IDF writing group included several mem-
bers of the original WHO consultation group. They liked the
ATP III definition because of its clinical simplicity. They
furthermore considered that abdominal obesity is so highly
correlated with insulin resistance that other, more laborious
measures of insulin resistance are unnecessary. The IDF
clinical definition thus makes the presence of abdominal
obesity necessary for diagnosis. When such is present, 2
additional factors originally listed in the ATP III definition
are sufficient for diagnosis. IDF recognized and emphasized
ethnic differences in the correlation between abdominal
obesity and other metabolic syndrome risk factors. For this
reason, criteria of abdominal obesity were specified by
nationality or ethnicity based on best available population
estimates. For people of European origin (Europid), the IDF
specified thresholds for abdominal obesity to be waist cir-
cumferences 94 cm in men and 80 cm in women. These
thresholds apply to Europids living in the Americas as well as
Europe. For Asian populations, except for Japan, thresholds
were 90 cm in men and 80 cm in women; for Japanese
they were 85 cm for men and 90 cm for women.
The present AHA/NHLBI statement, in contrast to IDF,
maintains the ATP III criteria except for minor modifications
(Table 2). This decision is based on the conclusion that ATP
III criteria are simple to use in a clinical setting and have the
advantage of avoiding emphasis on a single cause. No
compelling reasons were found for making a change. In
addition, a large number of studies have been carried out to
evaluate the ATP III criteria for the metabolic syn-
drome.35,111–133 The majority of these reports are supportive
of the present structure of ATP III criteria. It must be noted in
Table 2, however, that the threshold for IFG was reduced
from 110 to 100 mg/dL; this adjustment corresponds to the
recently modified American Diabetes Association (ADA)
criteria for IFG.134 Otherwise, the statement maintains that
continuity with the original ATP III definition, which has
been widely adopted in the United States and elsewhere, is
appropriate in the absence of new evidence to the contrary.
Present diagnostic criteria thus accord with ATP III by
defining abdominal obesity as a waist circumference of102
cm (40 in) for men and 88 cm (35 in) for women. As
noted in ATP III,1 some people will manifest features of
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insulin resistance and the metabolic syndrome with only
moderate increases in waist circumference (ie, between 94
and 101 cm in men or 80 and 87 cm in women). Among the
characteristics that may predispose to insulin resistance and
metabolic syndrome in such individuals are the following: (1)
type 2 diabetes mellitus in first-degree relatives before age 60
years,109 (2) polycystic ovary disease,9 (3) fatty liver,135 (4)
C-reactive protein (CRP) 3 mg/L (if measured),96 (5)
microalbuminuria (if detected),136–141 (6) impaired glucose
tolerance (if measured),109 and (7) elevated total apoB (if
measured).88,89 In addition, some populations are predisposed
to insulin resistance, metabolic syndrome, and type 2 diabetes
mellitus, with only moderate increases in waist circumference
(ie, populations from South Asia, China, Japan, and other
Asian countries).127,130,131,142 None of these phenotypic fea-
tures or ethnic differences was included in the ATP III
diagnostic criteria; but if individuals with such characteristics
have only moderate elevations of waist circumference plus at
least 2 ATP III metabolic syndrome features, then consider-
ation should be given to managing them similarly to people
with 3 ATP III risk factors.
The recent IDF definition of metabolic syndrome is similar
in practice to the modified ATP III definition adopted in the
present statement. Obvious differences are 2-fold: IDF re-
quires abdominal obesity as 1 factor and sets lower thresholds
for abdominal obesity than used in the United States. Even so,
most subjects with waist circumference 94 cm in men or
80 cm in women plus 2 other risk factors (IDF definition)
will in fact have 3 risk factors (ATP III definition). The
defining third risk factor will be either a higher waist
circumference (102 cm for men and88 cm for women) or
1 other risk component. For this reason, in the United States,
for the most part the same individuals will be identified by
either definition. At the same time, when applying ATP III
criteria in Asian countries, lower waist circumferences, as
defined by IDF for these populations, appear to be appropri-
ate as 1 risk factor.127,130,131,142 The same waist criteria are
reasonable for Asians living in the United States (Table 2).
Clinical Management of the
Metabolic Syndrome
Goals of Clinical Management
The primary goal of clinical management in individuals with
the metabolic syndrome is to reduce risk for clinical athero-
sclerotic disease. Even in people with the metabolic syn-
drome, first-line therapy is directed toward the major risk
factors: LDL-C above goal, hypertension, and diabetes.
Prevention of type 2 diabetes mellitus is another important
goal when it is not present in a person with the metabolic
syndrome. For individuals with established diabetes, risk
factor management must be intensified to diminish their
higher risk for ASCVD. The prime emphasis in management
of the metabolic syndrome per se is to mitigate the modifi-
able, underlying risk factors (obesity, physical inactivity, and
atherogenic diet) through lifestyle changes. Effective lifestyle
change will reduce all of the metabolic risk factors. Then, if
absolute risk is high enough, consideration can be given to
incorporating drug therapy to the regimen. The priority of
drug therapy is elevations of LDL-C, blood pressure, and
glucose; current guidelines for their management should be
followed. Moreover, efforts should be made to bring about
smoking cessation in any cigarette smokers.
Table 3 summarizes the current goals and recommenda-
tions for management of each of the risk factors of the
metabolic syndrome. These recommendations are derived in
large part from existing NHLBI, AHA, and ADA guidelines
for management of specific risk factors. It is important to note
that individuals who have established ASCVD and/or diabe-
tes can still have the metabolic syndrome. The evidence bases
for most of the recommendations have been presented in
background documents for obesity,108 physical inactivity,143
lipids,1 high blood pressure,91 and diabetes.134 The present
TABLE 2. Criteria for Clinical Diagnosis of
Metabolic Syndrome
Measure (any 3 of 5 constitute
diagnosis of metabolic syndrome) Categorical Cutpoints
Elevated waist circumference*† 102 cm (40 inches) in men
88 cm (35 inches) in women
Elevated triglycerides 150 mg/dL (1.7 mmol/L)
or
On drug treatment for elevated
triglycerides‡
Reduced HDL-C 40 mg/dL (1.03 mmol/L) in men
50 mg/dL (1.3 mmol/L) in women
or
On drug treatment for reduced
HDL-C‡
Elevated blood pressure 130 mm Hg systolic blood pressure
or
85 mm Hg diastolic blood pressure
or
On antihypertensive drug treatment in
a patient with a history of
hypertension
Elevated fasting glucose 100 mg/dL
or
On drug treatment for elevated
glucose
*To measure waist circumference, locate top of right iliac crest. Place a
measuring tape in a horizontal plane around abdomen at level of iliac crest.
Before reading tape measure, ensure that tape is snug but does not compress
the skin and is parallel to floor. Measurement is made at the end of a normal
expiration.
†Some US adults of non-Asian origin (eg, white, black, Hispanic) with
marginally increased waist circumference (eg, 94–101 cm [37–39 inches] in
men and 80–87 cm [31–34 inches] in women) may have strong genetic
contribution to insulin resistance and should benefit from changes in lifestyle
habits, similar to men with categorical increases in waist circumference. Lower
waist circumference cutpoint (eg,90 cm [35 inches] in men and80 cm [31
inches] in women) appears to be appropriate for Asian Americans.
‡Fibrates and nicotinic acid are the most commonly used drugs for elevated
TG and reduced HDL-C. Patients taking one of these drugs are presumed to
have high TG and low HDL.
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statement attempts to provide an integrated approach to the
management of a multidimensional risk factor condition.
Risk Assessment
ASCVD
A series of studies63–73 have found that many middle-aged
people with the metabolic syndrome are at increased absolute
risk for ASCVD in the near future (eg, 10-year risk).
Moreover, as stated previously, because of the high relative
risk for ASCVD, long-term (lifetime) risk for ASCVD is
increased even when 10-year risk is not considered to be high,
eg, in young adults who develop the syndrome. An exacer-
bating factor raising lifetime risk for ASCVD is an increased
likelihood for developing premature type 2 diabetes mellitus.
To reduce lifetime risk for ASCVD, all individuals found
to have the metabolic syndrome deserve long-term manage-
ment and follow-up in the clinical setting. The primary aim is
to reduce the underlying risk factors. Such individuals need to
be categorized according to absolute 10-year risk.1 Individu-
als with any clinical form of ASCVD or with diabetes belong
in the high-risk category.1 For metabolic syndrome patients
without ASCVD or diabetes, Framingham risk scoring should
be performed to estimate 10-year risk for coronary heart
disease (CHD).1 This assessment triages patients into 3 risk
categories based on 10-year risk for CHD: high risk (10-year
risk 20%), moderately high risk (10-year risk 10% to 20%),
or lower to moderate risk (10-year risk 10%).
Thus, detecting metabolic syndrome is only one part of
overall risk assessment for cardiovascular disease. The met-
abolic syndrome per se is not an adequate tool to estimate
10-year risk for CHD. Although patients with the metabolic
syndrome are at higher lifetime risk, in the absence of
diabetes they do not necessarily have a high 10-year risk.
Estimating 10-year risk entails key risk factors beyond those
of the syndrome, ie, age, sex, smoking, and total cholesterol.
Moreover, risk factors of the metabolic syndrome are not
graded for severity as are the risk factors contained in
Framingham scoring. Framingham investigators find little or
no increase in predictive power for CHD by adding abdom-
inal obesity, triglycerides, or fasting glucose to their 10-year
risk algorithm.58,144 These factors come into play in the longer
term. Whether adding still other factors—apoB, small LDL,
CRP, and insulin levels—will enhance shorter-term predic-
tion of ASCVD has not been rigorously tested in multivari-
able models.
Type 2 Diabetes Mellitus
In individuals with diabetes, the coexistence of other meta-
bolic syndrome factors denotes a higher risk for future
development of ASCVD.69 Compared with other metabolic
risk factors, IFG (fasting glucose 100 to 125 mg/dL) carries
the greatest predictive power for diabetes.112 A closely related
measure is IGT, defined as a 2-hour plasma glucose 140
mg/dL and 200 mg/dL observed during a standard oral
glucose tolerance test (OGTT). The ADA has introduced the
term “prediabetes” to apply to individuals with either IFG or
IGT.134 Some investigators recommend OGTT for normogly-
cemic subjects who have the metabolic syndrome to detect
IGT or occult diabetes. IGT in fact exceeds IFG in frequency;
it consequently uncovers more individuals at increased risk
for diabetes. In part to reduce the need for OGTT in routine
practice, the ADA recently reduced the threshold for IFG to
100 mg/dL, from its previous 110 mg/dL.134 People who have
fasting glucose in the range of 100 to 110 mg/dL are now said
to have IFG; many such people would have IGT if tested by
OGTT. OGTT nonetheless remains an option in normogly-
cemic individuals who appear to be at elevated risk for
developing diabetes. In fact, performing OGTT in people
with IFG will identify some individuals who already have
type 2 diabetes mellitus. Intensive lifestyle management of
individuals with IFG (or IGT) will delay conversion to type 2
diabetes mellitus.145
Management of Underlying Risk Factors
Although many people may be genetically susceptible to the
metabolic syndrome, rarely does it become clinically mani-
fested in the absence of some degree of obesity and physical
inactivity. Consequently, therapies to mitigate these underly-
ing risk factors constitute first-line intervention. If cigarette
smoking, another risk factor for ASCVD, is present, then it
likewise deserves intensive cessation effort. The reason to
modify underlying risk factors is to prevent or delay onset of
ASCVD; and if type 2 diabetes mellitus is not already
present, a concomitant goal is to prevent it as well.
Abdominal Obesity
Weight reduction deserves first priority in individuals with
abdominal obesity and the metabolic syndrome.108,146 Both
weight reduction and maintenance of a lower weight are best
achieved by a combination of reduced caloric intake and
increased physical activity and the use of principles of
behavior change. The first aim of weight loss is to achieve a
decline of about 7% to 10% from baseline total body weight
during a period of 6 to 12 months. This will require
decreasing caloric intake by 500 to 1000 calories per day.
Greater physical activity helps to enhance caloric deficit.
Achieving the recommended amount of weight loss will
reduce the severity of most or all of the metabolic risk factors.
Maintenance of a lower weight is just as important; this
requires long-term follow-up and monitoring.108
Currently available weight-loss drugs possess limited util-
ity in the management of obesity. Nevertheless, in some
patients they may be helpful. Bariatric surgery is being used
increasingly in the United States for severe obesity. Individ-
uals at high risk for the complications of obesity may benefit.
Weight-loss surgery is not without risk, however. Selection of
patients must be made with a team of healthcare professionals
who are qualified to make appropriate clinical judgments
about the pros and cons of this approach.
Physical Inactivity
Increasing physical activity assists in weight reduction; it also
has beneficial effects on metabolic risk factors; and impor-
tantly, it reduces overall ASCVD risk.147 Current recommen-
dations for the public call for accumulation of 30 minutes
of moderate-intensity exercise, such as brisk walking, on
most, and preferably all, days of the week77,143; even more
exercise adds more benefit. Thus, going beyond current
recommendations will be particularly beneficial for people
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TABLE 3. Therapeutic Goals and Recommendations for Clinical Management of Metabolic Syndrome
Therapeutic Target and Goals of Therapy Therapeutic Recommendations
Lifestyle risk factors Long-term prevention of CVD and prevention (or treatment) of type 2 diabetes mellitus
Abdominal obesity
Reduce body weight by 7% to 10% during year
1 of therapy. Continue weight loss thereafter to
extent possible with goal to ultimately achieve
desirable weight (BMI 25 kg/m2)
Consistently encourage weight maintenance/reduction through appropriate balance of physical activity, caloric intake, and formal
behavior-modification programs when indicated to maintain/achieve waist circumference of 40 inches in men and 35 inches in women.
Aim initially at slow reduction of 7% to 10% from baseline weight. Even small amounts of weight loss are associated with significant
health benefits.
Physical inactivity
Regular moderate-intensity physical activity; at
least 30 min of continuous or intermittent (and
preferably 60 min) 5 d/wk, but preferably
daily
In patients with established CVD, assess risk with detailed physical activity history and/or an exercise test, to guide prescription.
Encourage 30 to 60 min of moderate-intensity aerobic activity: brisk walking, preferably daily, supplemented by increase in daily lifestyle
activities (eg, pedometer step tracking, walking breaks at work, gardening, housework). Longer exercise times can be achieved by
accumulating exercise throughout day. Encourage resistance training 2 d/wk. Advise medically supervised programs for high-risk patients (eg,
recent acute coronary syndrome or revascularization, CHF).
Atherogenic diet
Reduced intake of saturated fat, trans fat,
cholesterol
Recommendations: saturated fat 7% of total calories; reduce trans fat; dietary cholesterol 200 mg/dL; total fat 25% to 35% of total
calories. Most dietary fat should be unsaturated; simple sugars should be limited.
Metabolic risk factors Shorter-term prevention of CVD or treatment of type 2 diabetes mellitus
Atherogenic dyslipidemia
Primary target: elevated LDL-C (see Table 4 for
details)
Secondary target: elevated non-HDL-C
Elevated LDL-C (see Table 4 for details)
Elevated non-HDL-C
High-risk patients*: 130 mg/dL
(3.4 mmol/L) (optional: 100 mg/dL
[2.6 mmol/L] for very high-risk patients†)
Moderately high-risk patients‡: 160 mg/dL
(4.1 mmol/L)
Therapeutic option: 130 mg/dL
(3.4 mmol/L)
Moderate-risk patients§: 160 mg/dL
(4.1 mmol/L)
Lower-risk patients: 190 mg/dL
(4.9 mmol/L)
Follow strategy outlined in Table 4 to achieve goal for LDL-C
First option to achieve non-HDL-C goal: Intensify LDL-lowering therapy
Second option to achieve non-HDL-C goal: Add fibrate (preferably fenofibrate) or nicotinic acid if non-HDL-C remains relatively high
after LDL-lowering drug therapy
Give preference to adding fibrate or nicotinic acid in high-risk patients
Give preference to avoiding addition of fibrate or nicotinic acid in moderately high-risk or moderate-risk patients
All patients: If TG is 500 mg/dL, initiate fibrate or nicotinic acid (before LDL-lowering therapy; treat non-HDL-C to goal after TG-lowering
therapy)
Tertiary target: reduced HDL-C Reduced HDL-C
No specific goal: Raise HDL-C to extent
possible with standard therapies for
atherogenic dyslipidemia
Maximize lifestyle therapies: weight reduction and increased physical activity
Consider adding fibrate or nicotinic acid after LDL-C-lowering drug therapy as outlined for elevated non-HDL-C
Elevated BP
Reduce BP to at least achieve BP of
140/90 mm Hg (or 130/80 mm Hg if
diabetes present). Reduce BP further to extent
possible through lifestyle changes.
For BP 120/80 mm Hg: Initiate or maintain lifestyle modification in all patients with metabolic syndrome: weight control, increased physical
activity, alcohol moderation, sodium reduction, and emphasis on increased consumption of fresh fruits, vegetables, and low-fat dairy products
For BP 140/90 mm Hg (or 130/80 mm Hg for individuals with chronic kidney disease or diabetes): As tolerated, add BP medication as
needed to achieve goal BP
Elevated glucose
For IFG, delay progression to type 2 diabetes
mellitus. For diabetes, hemoglobin A1C 7.0%
For IFG, encourage weight reduction and increased physical activity.
For type 2 diabetes mellitus, lifestyle therapy, and pharmacotherapy, if necessary, should be used to achieve near-normal HbA1C (7%).
Modify other risk factors and behaviors (eg, abdominal obesity, physical inactivity, elevated BP, lipid abnormalities).
Prothrombotic state
Reduce thrombotic and fibrinolytic risk factors High-risk patients: Initiate and continue low-dose aspirin therapy; in patients with ASCVD, consider clopidogrel if aspirin is contraindicated.
Moderately high-risk patients: Consider low-dose aspirin prophylaxis
Proinflammatory state Recommendations: no specific therapies beyond lifestyle therapies
TG indicates triglycerides; BP, blood pressure; CVD, cardiovascular disease; CHF, congestive heart failure; BMI, body mass index; IFG, impaired fasting glucose;
and ASCVD, atherosclerotic cardiovascular disease.
*High-risk patients are those with established ASCVD, diabetes, or 10-year risk for coronary heart disease 20%. For cerebrovascular disease, high-risk condition
includes TIA or stroke of carotid origin or 50% carotid stenosis.
†Very high-risk patients are those who are likely to have major CVD events in next few years, and diagnosis depends on clinical assessment. Factors that may
confer very high risk include recent acute coronary syndromes, and established coronary heart disease  any of following: multiple major risk factors (especially
diabetes), severe and poorly controlled risk factors (especially continued cigarette smoking), and metabolic syndrome.
‡Moderately high-risk patients are those with 10-year risk for coronary heart disease 10% to 20%. Factors that favor therapeutic option of non-HDL-C100 mg/dL
are those that can raise individuals to upper range of moderately high risk: multiple major risk factors, severe and poorly controlled risk factors (especially continued
cigarette smoking), metabolic syndrome, and documented advanced subclinical atherosclerotic disease (eg, coronary calcium or carotid intimal-medial thickness
75th percentile for age and sex).
§Moderate-risk patients are those with 2 major risk factors and 10-year risk 10%.
Lower-risk patients are those with 0 or 1 major risk factor and 10-year risk 10%.
Grundy et al Diagnosis and Management of the Metabolic Syndrome 2741
 by guest on M
arch 28, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
with the metabolic syndrome. Sixty minutes or more of
continuous or intermittent aerobic activity, preferably done
every day, will promote weight loss or weight-loss mainte-
nance. Preference is given to 60 minutes of moderate-
intensity brisk walking to be supplemented by other activi-
ties.77 The latter include multiple short (10- to 15-minute)
bouts of activity (walking breaks at work, gardening, or
household work), using simple exercise equipment (eg, tread-
mills), jogging, swimming, biking, golfing, team sports, and
engaging in resistance training148; avoiding common seden-
tary activities in leisure time (television watching and com-
puter games) is also advised. Self-monitoring of physical
activity can help to achieve adherence to an activity program.
Current AHA guidelines143 call for clinical assessment of
risk for future ASCVD events before initiating a new exercise
regimen. This includes a detailed history of physical activity.
For high-risk patients (eg, those with recent acute coronary
syndromes or recent revascularization), physical activity
should be carried out under medical supervision. AHA
guidelines143 further recommend exercise testing before vig-
orous exercise in selected patients with cardiovascular dis-
ease and other patients with symptoms or those at high risk.
It is not necessary, however, that all individuals beginning an
exercise program of moderate intensity that is moderately
progressive undergo an exercise stress test, although this
issue remains controversial.
Atherogenic and Diabetogenic Diets
Beyond weight control and reduction of total calories, the diet
should be low in saturated fats, trans fats, cholesterol,
sodium, and simple sugars.1,149 In addition, there should be
ample intakes of fruits, vegetables, and whole grains; fish
intake should be encouraged with recognition of concerns
about the mercury content of some fish (see the Food and
Drug Administration web site, www.cfsan.fda.gov/dms/
admehg3.html).91,150,151 Very high carbohydrate intakes can
exacerbate the dyslipidemia of the metabolic syndrome. ATP
III1 recommended that for individuals entering cholesterol
management the diet should contain 25% to 35% of calories
as total fat. If the fat content exceeds 35%, it is difficult to
sustain the low intakes of saturated fat required to maintain a
low LDL-C. On the other hand, if the fat content falls below
25%, triglycerides can rise and HDL-C levels can decline152;
thus, very-low-fat diets may exacerbate atherogenic dyslip-
idemia. To avoid any worsening of atherogenic dyslipidemia
in patients with the metabolic syndrome, some investigators
favor fat intakes in the range of 30% to 35%; others, however,
are concerned about possible weight gain resulting from
long-term ingestion of higher fat intakes and thus prefer
intakes in the range of 25% to 30%.
There has long been an interest in the question of whether
changing the macronutrient content of the diet can promote
weight reduction. For many years, a low-fat diet was advo-
cated because the high caloric density of fat could increase
the likelihood of obesity. More recently, interest has grown in
the possibility that high-protein, low-carbohydrate diets will
enhance weight reduction.153 The rationale seems to be that
fat and protein offer satiety that is absent with carbohydrates.
That this effect of fat and protein on satiety makes the diet
more effective for producing weight loss is a disputable
hypothesis. Moreover, research documenting that high-fat/
high-protein/low-calorie diets can achieve long-term mainte-
nance of a lower body weight is lacking. In fact, after 1 year
of consumption of low-carbohydrate diets, severely obese
patients show no more weight reduction than those eating a
conventional weight-loss diet.154 High-fat diets not only tend
to be higher in saturated fat but they often are deficient in
fruits, vegetables, and whole grains—all of which are impor-
tant components in currently recommended diets. High-
protein diets of any sort are not well tolerated by individuals
with chronic renal disease who have markedly reduced
glomerular filtration rate; excess protein enhances phospho-
rus load, which can cause acidosis and worsen insulin
resistance.155,156 Finally, preoccupation with macronutrient
composition to promote weight loss fails to identify the key
factors affecting body weight. Effective weight loss requires
a combination of caloric restriction, physical activity, and
motivation; effective lifelong maintenance of weight loss
essentially requires a balance between caloric intake and
physical activity.
Management of Metabolic Risk Factors
Beyond lifestyle therapies directed toward underlying risk
factors, attention must be given to the metabolic risk factors.
If ASCVD or diabetes is present, or if the 10-year risk as
determined by Framingham risk factors is relatively high,
then drug therapies for risk factors may be required as defined
by current guidelines.1,91,134 Recommended principles of
management for each of the metabolic risk factors are also
considered in Table 3.
Atherogenic Dyslipidemia
As noted before, this condition consists of abnormal levels of
triglycerides and apoB, small LDL particles, and low HDL-C.
According to ATP III,1 atherogenic dyslipidemia can become
a target for lipid-lowering therapy after the goal for LDL-C
has been attained. In other words, as long as LDL-C remains
above goal level, LDL-C is the primary target of therapy even
in the metabolic syndrome. Other lipid risk factors are
secondary. The LDL-C goals depend on estimates of absolute
risk. Table 4 reviews LDL-C goals that are consistent with
recommendations of ATP III1 and its recent update.157 In
patients with atherogenic dyslipidemia in whom serum tri-
glyceride levels are 200 mg/dL, non-HDL-C becomes the
next target of treatment after the LDL-C goal is reached
(Table 3). A related and potential secondary target is an
elevated total apoB158; this measure denotes the number of
atherogenic lipoproteins in circulation.85–89 Some investiga-
tors hold that total apoB is superior to non-HDL-C as a target
of lipid-lowering therapy.89,159,160 ATP III nonetheless iden-
tified non-HDL-C rather than total apoB as a secondary target
(after LDL-C) because accurate measurement of non-HDL-C
is more readily available in clinical practice. Goals for
non-HDL-C parallel those for LDL-C except that the former
are 30 mg/dL higher (Table 3).
When triglycerides are 500 mg/dL, triglyceride-lowering
drugs should be considered to prevent the development of
acute pancreatitis.1 To achieve non-HDL-C goals at triglyc-
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erides 500 mg/dL, triglyceride-lowering drugs may be
useful in combination with LDL-lowering therapy. Beyond
lowering of non-HDL-C, a tertiary aim in patients with
atherogenic dyslipidemia is to raise HDL-C when it is
reduced. No specific goal of therapy is recommended for low
HDL-C, but HDL-C should be raised to the extent possible
after attaining goals for LDL-C and non-HDL-C.
If non-HDL-C remains elevated after the LDL-C goal is
reached (Table 4), at least 2 therapeutic options are available.
First, intensification of LDL lowering often also reduces
non-HDL-C. For example, statins lower both LDL-C and
non-HDL-C by a similar percentage; moreover, statins reduce
risk for ASCVD events in patients with the metabolic
syndrome.161 Second, a triglyceride-lowering drug can be
added to LDL-lowering therapy. Both fibrates and nicotinic
acid reduce non-HDL-C and reportedly decrease risk for
ASCVD in patients with the metabolic syndrome/type 2
diabetes mellitus.162–164 For this reason, combining a fibrate
or nicotinic acid with LDL-C-lowering treatment becomes an
option.165,166 Both fibrates and nicotinic acid raise HDL-C as
well as reduce triglycerides and small LDL particles. If a
statin is being used for LDL-C lowering, fenofibrate seems
preferable to gemfibrozil because risk for severe myopathy
appears to be lower for fenofibrate in combination with
statins.167 One recent report,168 however, failed to find a
difference in myopathy risk between gemfibrozil and fenofi-
brate when either was used in combination with statins (other
than cerivastatin, which is no longer available). Patients with
IFG, IGT, or diabetes who are treated with nicotinic acid
deserve careful monitoring for worsening of hyperglyce-
mia.169 Lower doses of nicotinic acid lessen this risk.
Whether adding a fibrate or nicotinic acid to statin therapy
will reduce cardiovascular events more than a statin alone has
not been evaluated adequately in randomized clinical trials;
consequently the use of this combination probably should be
limited largely to high-risk individuals who stand to gain the
most from it. If a fibrate or nicotinic acid is used with a statin,
higher doses of the statin generally should be avoided to
minimize risks for myopathy or hepatic effects.
Elevated Blood Pressure
When overt hypertension is present without diabetes or
chronic kidney disease, the goal for antihypertensive therapy
is a blood pressure of 140/90 mm Hg.91 In the presence of
diabetes or chronic kidney disease, the blood pressure goal is
130/80 mm Hg.91 Beyond these specific treatment goals,
lifestyle changes deserve increased emphasis in people with
the metabolic syndrome; the goals here are to reduce blood
pressure as much as possible even in the absence of overt
hypertension and to obtain other metabolic benefits of life-
style change. Mild elevations of blood pressure often can be
effectively controlled with lifestyle therapies: weight control,
increased physical activity, alcohol moderation, sodium re-
duction, and increased consumption of fresh fruits and
vegetables and low-fat dairy products, in accord with the
Dietary Approaches to Stop Hypertension (DASH) diet.91 If
hypertension cannot be adequately controlled by lifestyle
TABLE 4. Elevated LDL-C: Primary Target of Lipid-Lowering Therapy in People at Risk for ASCVD
Goals of Therapy Therapeutic Recommendations
High-risk patients*: 100 mg/dL (2.6 mmol/L) (for High-risk patients: lifestyle therapies† plus LDL-C-lowering drug to achieve recommended goal
very high-risk patients‡ in this category, optional goal If baseline LDL-C 100 mg/dL, initiate LDL-lowering drug therapy
70 mg/dL) If on-treatment LDL-C 100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering
drug combination)
If baseline LDL-C 100 mg/dL, initiate LDL-lowering therapy based on clinical judgment (ie,
assessment that patient is at very high risk)
Moderately high-risk patients§: 130 mg/dL
(3.4 mmol/L) (for higher-risk patients in this category,
optional goal is 100 mg/dL (2.6 mmol/L)
Moderately high-risk patients: lifestyle therapiesLDL-lowering drug if necessary to achieve
recommended goal when LDL-C 130 mg/dL (3.4 mmol/L) after lifestyle therapies
If baseline LDL-C is 100 to 129 mg/dL, LDL-lowering therapy can be introduced if patient’s risk is
assessed to be in upper ranges of this risk category
Moderate-risk patients¶: 130 mg/dL (3.4 mmol/L) Moderate risk patients: lifestyle therapiesLDL-C lowering drug if necessary to achieve recommended
goal when LDL-C 160 mg/dL (4.1 mmol/L) after lifestyle therapies
Lower-risk patients#: 160 mg/dL (4.9 mmol/L) Lower-risk patients: lifestyle therapiesLDL-C lowering drug if necessary to achieve recommended
goal when LDL-C 190 mg/dL after lifestyle therapies (for LDL-C 160 to 189 mg/dL, LDL-lowering
drug is optional)
*High-risk patients are those with established ASCVD, diabetes, or 10-year risk for coronary heart disease 20%. For cerebrovascular disease, high-risk condition
includes transient ischemic attack or stroke of carotid origin or 50% carotid stenosis.
†Lifestyle therapies include weight reduction, increased physical activity, and antiatherogenic diet (see Table 3 for details).
‡Very high-risk patients are those who are likely to have major CVD events in next few years, and diagnosis depends on clinical assessment. Factors that may
confer very high risk include recent acute coronary syndromes, and established coronary heart diseaseany of following: multiple major risk factors (especially
diabetes), severe and poorly controlled risk factors (especially continued cigarette smoking), and multiple risk factors of metabolic syndrome.
§Moderately high-risk patients are those with 10-year risk for coronary heart disease 10% to 20%.
Factors that can raise individuals to upper range of moderately high risk are multiple major risk factors, severe and poorly controlled risk factors (especially
continued cigarette smoking), metabolic syndrome, and documented advanced subclinical atherosclerotic disease (eg, coronary calcium or carotid intimal-medial
thickness 75th percentile for age and sex).
¶Moderate-risk patients are those with 2 major risk factors and 10-year risk 10%.
#Lower-risk patients are those with 0 or 1 major risk factor and 10-year risk 10%.
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therapies, antihypertensive drugs usually are necessary to
prevent long-term adverse effects, eg, myocardial infarction,
stroke, and chronic kidney disease.91 The benefits of therapy
extend to patients with type 2 diabetes mellitus whose blood
pressure is above goal level, and presumably to hypertensive
patients with the metabolic syndrome. Some investigators
support angiotensin-converting enzyme (ACE) inhibitors as
first-line therapy for hypertension in the metabolic syndrome,
especially when either type 2 diabetes mellitus or chronic
renal disease is present.170 Indeed, inhibition of the renin-an-
giotensin system with ACE inhibitors or angiotensin receptor
blockers (ARBs) may lower risk for diabetes itself.171 ARBs
may be used in those who cannot tolerate ACE inhibitors or
as an alternative to ACE inhibitors in people who have left
ventricular dysfunction.172 Debate persists about the latter
strategy. The results of a large clinical trial173 raised the
possibility that use of diuretics in patients with IFG or IGT
may increase the likelihood of progression to type 2 diabetes
mellitus, although diuretics do in fact lower the risk for
cardiovascular events.91,173 Most investigators in the hyper-
tension field believe that the potential benefit of low-dose
diuretics in combination antihypertensive therapy outweighs
their risk.
Elevated Fasting Glucose
In the metabolic syndrome diagnosis, elevated fasting glucose
(100 mg/dL) includes both IFG and type 2 diabetes melli-
tus. In metabolic syndrome patients with IFG (or IGT if
assessed), weight reduction, increased physical activity, or
both will delay (or prevent) the onset of type 2 diabetes
mellitus.145,174 In addition, metformin,145 thiazolidinedio-
nes,175,176 and acarbose177 will lower risk for type 2 diabetes
mellitus in people with IFG or IGT. Except for a preliminary
trial with acarbose,178 no clinical trial evidence is yet avail-
able to document that oral hypoglycemic agents will lessen
risk for cardiovascular events. Moreover, neither metformin
nor thiazolidinediones are recommended in this statement
solely for the purpose of preventing diabetes because their
cost-effectiveness and long-term safety have not been
documented.
For patients with established type 2 diabetes mellitus,
clinical trials confirm a reduction in cardiovascular risk from
treatment of dyslipidemia161–163,179–181 and hypertension.91
Glycemic control to a hemoglobin A1c of 7% reduces
microvascular complications and may decrease risk for ma-
crovascular disease as well.182
Prothrombotic State
People with the metabolic syndrome typically manifest ele-
vations of fibrinogen, plasminogen activator inhibitor-1, and
other coagulation factors. These abnormalities, however, are
not routinely detected in clinical practice. For primary pre-
vention, the only available long-term approach to counter
their contribution to arterial thrombosis is low-dose aspirin or
other antiplatelet agents. These agents, especially aspirin, are
recommended in patients with established ASCVD provided
they are not contraindicated. Their efficacy in individuals
with type 2 diabetes mellitus without ASCVD has not been
established conclusively through clinical trials, although they
are widely recommended in such individuals. In metabolic
syndrome patients who are at moderately high risk for
ASCVD events, aspirin prophylaxis is an attractive therapeu-
tic option to lower vascular events.183
Proinflammatory State
People with the metabolic syndrome frequently have a
proinflammatory state as shown by elevated cytokines (eg,
tumor necrosis factor- and interleukin-6) and acute-phase
reactants (eg, CRP, fibrinogen).96,184 Measurement of CRP is
the simplest way to identify a proinflammatory state in
clinical practice. CRP levels 3 mg/L can be taken to define
such a state in a person without other detectable causes.95 If
CRP is measured, the finding of an elevated level supports the
need for lifestyle changes. The latter, particularly weight
reduction, will reduce CRP levels and presumably will
mitigate the underlying inflammatory stimulus.185 No drugs
that act exclusively through this mechanism are available for
reducing cardiovascular risk. However, several drugs used to
TABLE 5. Additional Measures Reported to Be Associated
With Metabolic Syndrome and in Need of More Research
Abnormal body fat distribution
General body fat distribution (dual-energy x-ray absorptiometry [DXA])
Central fat distribution (CT/MRI)
Adipose tissue biomarkers: leptin, adiponectin
Liver fat content (magnetic resonance spectroscopy)
Myocellular fat (magnetic resonance spectroscopy)
Atherogenic dyslipidemia (beyond elevated triglyceride and non-HDL-C
and low HDL)
Apolipoprotein B
Small LDL particles
Triglycerides/HDL-C ratios
Dysglycemia
Fasting glucose
OGTT
Insulin resistance (other than elevated fasting glucose)
Fasting insulin/proinsulin levels
Homeostasis model assessment for insulin resistance (HOMA-IR)
Insulin resistance by Bergman Minimal Model
Elevated free fatty acids (fasting and during OGTT)
Vascular dysregulation (beyond elevated blood pressure)
Measurement of endothelial dysfunction
Microalbuminura
Chronic renal disease
Proinflammatory state
Elevated high-sensitivity CRP
Elevated inflammatory cytokines (eg, interleukin-6)
Low levels of adiponectin
Prothrombotic state
Fibrinolytic factors (plasminogen activator inhibitor-1, etc)
Clotting factors (fibrinogen, etc)
Hormonal factors
Corticosteroid axis
Polycystic ovary syndrome
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treat other metabolic risk factors have been reported to reduce
CRP levels (eg, statins, nicotinic acid, fibrates, ACE inhibi-
tors, thiazolidinediones).186–188 At present, these drugs cannot
be recommended specifically to reduce a proinflammatory
state independent of their indications for other risk factors.
Future Research
This statement recognizes several issues related to the meta-
bolic syndrome that require additional research for clarifica-
tion. Foremost is the need for improved strategies to achieve
and sustain long-term weight reduction and increased physi-
cal activity. Moreover, a lack of understanding of the genetic
and metabolic contributions to the causation of the syndrome
stands in the way of developing new therapeutic approaches.
The need exists, therefore, for additional basic and clinical
research designed to better understand pathophysiology from
the standpoint of genetics, molecular biology, and cellular
signaling. At present, tools to assess short-term risk for
ASCVD and diabetes in patients with the metabolic syn-
drome need significant improvement. Although statins and
other LDL-lowering drugs effectively reduce the risk for
ASCVD, adequate therapies for remaining dyslipidemias
either are not available or have not yet been proved to reduce
risk in combination with LDL-lowering drugs. Insulin resis-
tance is an attractive target for prevention of ASCVD; clinical
trials to date, however, have not been carried out to confirm
ASCVD risk reduction from decreasing insulin resistance per
se. The emerging relationship between a proinflammatory
state and the development of both ASCVD and diabetes
deserves much additional investigation. Finally, the cost-
effectiveness of various drugs, both alone and in combination
therapies, requires more extensive evaluation.
The metabolic syndrome can be clinically manifested in a
variety of ways. A sizable number of metabolic changes thus
occur in people with clinical evidence of the syndrome. Identi-
fication of these changes should provide a broader picture of the
metabolic status of an affected individual. They may also give
insights into pathogenesis. At present, many of these factors
cannot be readily identified in routine clinical practice. Never-
theless, several factors appear to overlap with alternative mea-
sures of the same underlying or metabolic risk factor. For
example, there are several ways to estimate body fat distribution.
In addition, multiple tests for insulin resistance have been
proposed; each examines a different aspect of the insulin-
resistance phenomenon. The IDF report lists many of these
factors as important targets for research even when they are not
used for routine clinical diagnosis. Table 5 presents a list of
research targets similar to those proposed by the IDF. Epidemi-
ological, metabolic, and genetic studies directed to a broad
profile of parameters related to the metabolic syndrome should
provide new insights into the responsible pathways. It is not
expected that these measures will be used in routine clinical
practice because the incremental value of measurement is
uncertain. Their study at present is expected to be mainly for
research, ie, metabolic and epidemiological studies.
Conclusions
In summary, the following points should be emphasized:
1. The metabolic syndrome is a term for a constellation of
endogenous risk factors that increase the risk of develop-
ing both ASCVD and type 2 diabetes mellitus.
2. The syndrome is not a discrete entity known to be caused
by a single factor. Moreover, it shows considerable vari-
ation in the components among different individuals. This
variation is even greater among different racial and ethnic
groups.
3. In the United States, the syndrome is strongly associated
with the presence of abdominal obesity.
4. The metabolic syndrome is a secondary target for reducing
cardiovascular events. Smoking cessation, lowering the
levels of LDL-C, and blood pressure management are
primary targets for risk reduction.
5. Lifestyle interventions are the initial therapies recom-
mended for treatment of the metabolic syndrome. If
lifestyle change is not sufficient, then drug therapies for
abnormalities in the individual risk factors may be
indicated.
6. To date, there is insufficient evidence for primary use of
drugs that target the underlying causes of the metabolic
syndrome.
7. Considerable additional research is needed to better refine
the most appropriate therapies for individuals with the
metabolic syndrome.
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